The multistate outbreak of vaping-related lung injury is ongoing, but the CDC's updated interim guidance can help physicians navigate the clinical evaluation and management of these patients.
Dupilumab Potent Against Uncontrolled COPD with T2 Inflammation: BOREAS Trial Update
Reduced exacerbations, improved lung function, increased QoL, and less use of systemic corticosteroids underscore dupilumab's effects against type 2 inflammation.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Expert Panel Offers Guidance on Testing for COVID-19, Influenza, RSV During Respiratory Virus Season 2023-2024
As flu season approaches this year, experts stress that it's not just about influenza anymore; they discuss testing, antiviral treatment, and management of coinfection.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
FDA Approves First RSV Vaccine for Use in Pregnant Individuals to Prevent LRTD in Infants
The FDA approved Abrysvo for use in pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.
US Infants Admitted to ICU in 2022 for RSV Mostly Young, Healthy, and Born at Term
Approximately 80% of infants hospitalized with an RSV-related illness during the 2022 seasonal peak did not have underlying medical conditions, according to new study.